Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913/ |